R&D Projects
8
+
Patents
150
+
Time to IND Filing
Fastest
in
2
years
R&D Investment in 2024
US$25
million
FBDB™
Advantages of Our Technology Platform
Synergistically Re-Activating of Innate and Adaptive Immune Systems Multi targets strategy to eliminate Tumor Cells
Blockade of SIRPα/CD47 Signaling Pathway
Blockade of PD-1/PD-L1 Signaling Pathway
Modulation of the Tumor Microenvironment (TME) to Further Activate Macrophages and T Cells
News
HanchorBio Expands Clinical Evidence Supporting Its Macrophage-Directed Oncology Strategy
HanchorBio announced updated early clinical observations from its HCB101 program.
Jul 22, 2026
Read more
HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026
HanchorBio announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan.
Jul 13, 2026
Read more
HanchorBio and InxMed Sign Strategic MOU to Explore HCB101-Based Combination Therapies for Difficult-to-Treat Solid Tumors
HanchorBio announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (“MOU”) with InxMed (Shanghai) Co., Ltd. (“InxMed”).
Jul 08, 2026
Read more
HanchorBio Announces FDA Type C Meeting Minutes Supporting a Clear Development Path for HCB101 in Second-Line Gastric/GEJ Cancer
HanchorBio announced receipt of the official minutes from its recent U.S. Food and Drug Administration (FDA) Type C meeting regarding the post-Phase 1 development strategy for HCB101.
Jun 30, 2026
Read more
HanchorBio Showcases HCB101 Myeloid-Enhancer Strategy in Gastric Cancer and HNSCC at JCA-AACR 2026
HanchorBio, Inc announced poster presentations of HCB101 clinical data at the 9th Japanese Cancer Association (JCA) and the American Association for Cancer Research (AACR) Special Joint Conference on Novel Therapies and Diagnostics in Upper Digestive and Head and Neck Cancers, taking place June 28-30, 2026, in Kyoto, Japan.
Jun 30, 2026
Read more
HanchorBio to Attend BIO International Convention 2026 to Advance Global Partnering Opportunities
HanchorBio announced that Dr. Yuehua Cong, Chief Business Officer, will attend BIO International Convention 2026.
Jun 19, 2026
Read more
HanchorBio Presents Two Oral Presentations at ESMO TAT Asia 2026 Highlighting Progress Across Its Next-Generation Immunotherapy Pipeline
HanchorBio announced that two company-sponsored clinical programs were featured in oral presentations at the European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress 2026, ESMO TAT Asia 2026, held in Hong Kong.
Jun 13, 2026
Read more
HanchorBio Presents Late-Breaking Data at FOCIS 2026 Supporting Innate-Immune Product Engine Across Oncology and Autoimmune Disease
HanchorBio announced the presentation of late-breaking clinical and translational data at the Federation of Clinical Immunology Societies Annual Meeting, FOCIS 2026, being held June 9-12, 2026, in San Francisco.
Jun 10, 2026
Read more
HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress
HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Jun 01, 2026
Read more
HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
HanchorBio announced that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.
May 28, 2026
Read more
JOIN OUR TEAM
